Authors


Don Hannaford, Levick Strategic Communications

Latest:

Transparency Is the Solution to the Medical-Journal 'Ghostwriting' Controversy

Drug companies should keep a goal of effective communications as the priority in medical publications


General Manager of UL Compliance to Performance

Latest:

Managing employee training at the enterprise level

The case for a single enterprise-wide learning management system


Bob Celeste, RCG Partners

Latest:

Does healthcare benefit from a unified approach to item-level serialization and UDI?

"If we had asked them, they would have asked for faster horses." ~ Henry Ford


Paul Keckley, Deloitte Center for Health Solutions

Latest:

Deloitte 2010 Survey of Health Care Consumers

More personal control over healthcare and the desire for more access to information drive consumer attitudes



Chris Cobourn

Latest:

Lessons learned on bona fide service fees and fair market value-is there a 'right answer'?

Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial


Steve Stefano

Latest:

Specialty pharmaceuticals demand integrated patient and prescriber approaches

True 'market access' should involve coordinated approaches to patients and their healthcare providers


John Still, PharmaMetrics Inc.

Latest:

Finding the value in outsourced contract administration

The growing complexity of managed-markets contract support makes outsourcing a near-necessity for Small Pharma, and a better option for Big Pharma


Kevin Lawler, Pelican BioThermal

Latest:

2020 Cold Chain Forecast

Ushering in the Next Decade of Change


Lesley Kristeff, iGPS LLC

Latest:

Making Pallets a Supply Chain Asset Instead of an Unrecoverable Cost

Recent product contamination incidents are highlighting the importance of having reliably clean pallets for warehousing and shipping


By Pharmaceutical Commerce Staff

Latest:

Pacira BioSciences Announces FDA Approval of Expanded Indications for Exparel

Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.


Executive Chairman, Zephyr Health

Latest:

Powering up medical affairs

Technology is enabling more resources to reach the medical 
affairs teams—in a compliant manner


By Mike Elliot, Custom Vault Corp.

Latest:

Storing controlled substances safely and efficiently

Good design of vaults and cages for DEA-regulated materials calls for meeting regulatory requirements while accommodating operational practices


Kyle Forcier

Latest:

A 340B Navigation Guide for Pharmaceutical Manufacturers

How drugmakers can navigate the program’s pricing challenges and regulatory developments.


By Rohit Sood, Campbell Alliance

Latest:

Life Cycle Management Without Borders

Taking a market-by-market approach to maximizing value after loss of exclusivity


Jeremy Schafer, Michael Tapella

Latest:

Biosimilars: why deep discounts may become the dominant paradigm

European experience to date indicates a changing perspective on biosimilar pricing



Brian Rice, Priority Solutions

Latest:

Rethinking Sample Distribution

As the number of specific services associated with sample distribution has grown, so has the number of service providers a manufacturer might use. It’s time to think about consolidating these services


Jeff Siegel

Latest:

Oncology Networks Offer Distribution Alternatives

The recent acquisition of US Oncology by McKesson highlights the rising importance of the distributor-led networks


James Brown, Zinc Ahead

Latest:

Maintaining your digital marketing assets

Promotional content produced for, or derived from, digital media presents its own management and compliance complexities


Dan Piggott, Ashfield

Latest:

Specialty pharmaceuticals demand integrated patient and prescriber approaches

True 'market access' should involve coordinated approaches to patients and their healthcare providers


By Steve Lam, Senior Vice President, Patheon’s Biologics Unit

Latest:

Dealing with biologics production uncertainty

The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand


Cole Werble

Latest:

OPINION: Will Class-Wide REMS Programs Delay New Opioid Approvals?

Class-wide opioid REMS will affect four million patients and require cooperation of more than 25 drug manufacturers


Joe Slota, Marcos Buelvas

Latest:

Managing quality risks across the pharmaceutical supply chain

Well designed quality systems follow the product life cycle and foster a culture of quality



By Teresa Wilcox, RPh, PhD, Peter Marangos

Latest:

Evidence Generation Is the Foundation to Optimal Product Positioning

Evidence Generation Is the Foundation to Optimal Product Positioning


John Gray, Healthcare Distribution Management Assn.

Latest:

Collaboration key to a healthy supply chain in 2016

HDMA seeks to encourage more outreach to business partners and government


Minna Bak, Helio Health Group

Latest:

First physicians, now patients: Risk avoidance in patient support programs

A look into the growing compliance risks associated with patient services


Michael Casale, HealthBridge

Latest:

Six Essentials for the Next-Generation Sampling Platform

New technological capabilities will enable management of sample-distribution processes to keep up with a challenging environment


Nicola Smith, QuintilesIMS

Latest:

The growing role of clinical trial educators

Addressing patient recruitment and retention issues is a natural role for CTEs

© 2024 MJH Life Sciences

All rights reserved.